| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $4,318,214 | 5 | 100 |
| Friberg Gregory R | EVP, Chief R&D Officer | 0 | $0 | 2 | $558,619 | $-558,619 |
| Guyer Charles Greg | EVP, Chief Technical Officer | 0 | $0 | 1 | $996,744 | $-996,744 |
| Davis George Eric | EVP, Chief Legal Officer | 0 | $0 | 2 | $2.76M | $-2.76M |
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique …
Over the last 12 months, insiders at BioMarin Pharmaceutical Inc. have bought $0 and sold $4.32M worth of BioMarin Pharmaceutical Inc. stock.
On average, over the past 5 years, insiders at BioMarin Pharmaceutical Inc. have bought $314,469 and sold $14.99M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,625 shares for transaction amount of $314,469 was made by Alles Mark J (director) on 2022‑10‑31.
| 2026-09-02 | Sale | Davis George Eric | EVP, Chief Legal Officer | 17,557 0.009% | $66.28 | $1.16M | -14.08% | |
| 2026-05-07 | Sale | Friberg Gregory R | EVP, Chief R&D Officer | 3,281 0.0017% | $53.85 | $176,682 | +8.49% | |
| 2026-03-11 | Sale | Guyer Charles Greg | EVP, Chief Technical Officer | 16,486 0.0086% | $60.46 | $996,744 | -5.55% | |
| 2026-02-26 | Sale | Davis George Eric | EVP, Chief Legal Officer | 26,061 0.0136% | $61.36 | $1.6M | -6.25% | |
| 2026-02-26 | Sale | Friberg Gregory R | EVP, Chief R&D Officer | 6,326 0.0033% | $60.38 | $381,937 | -6.25% | |
| 2025-05-20 | Sale | Burkhart Erin | GVP, Chief Accounting Officer | 1,786 0.0009% | $59.31 | $105,928 | -6.37% | |
| 2025-05-02 | Sale | Hubbard Cristin | EVP, Chief Commercial Officer | 273 0.0001% | $64.92 | $17,723 | -8.83% | |
| 2025-03-19 | Sale | Burkhart Erin | GVP, Chief Accounting Officer | 1,295 0.0007% | $71.52 | $92,618 | -19.45% | |
| 2025-03-06 | Sale | Guyer Charles Greg | EVP, Chief Technical Officer | 7,034 0.0037% | $71.28 | $501,355 | -19.18% | |
| 2025-02-24 | Sale | Burkhart Erin | GVP, Chief Accounting Officer | 1,344 0.0007% | $68.38 | $91,903 | -16.61% | |
| 2024-11-12 | Sale | Guyer Charles Greg | EVP, Chief Technical Officer | 5,278 0.0028% | $66.37 | $350,324 | -10.43% | |
| 2024-08-13 | Sale | Burkhart Erin | GVP, Chief Accounting Officer | 714 0.0004% | $90.00 | $64,260 | -28.28% | |
| 2024-05-30 | Sale | Mueller Brian | EVP, Chief Financial Officer | 5,000 0.0027% | $75.19 | $375,950 | -7.26% | |
| 2024-05-28 | Sale | Davis George Eric | EVP, Chief Legal Officer | 40,850 0.0215% | $74.51 | $3.04M | -6.91% | |
| 2024-05-10 | Sale | BIENAIME JEAN JACQUES | director | 20,000 0.0105% | $81.14 | $1.62M | -13.49% | |
| 2024-05-09 | Sale | BIENAIME JEAN JACQUES | director | 20,000 0.0105% | $81.62 | $1.63M | -14.21% | |
| 2024-05-02 | Sale | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | 5,000 0.0026% | $82.91 | $414,550 | -16.14% | |
| 2024-05-02 | Sale | Davis George Eric | EVP, Chief Legal Officer | 1,850 0.001% | $85.01 | $157,269 | -16.14% | |
| 2024-04-12 | Sale | BIENAIME JEAN JACQUES | director | 20,000 0.0104% | $91.26 | $1.83M | -23.17% | |
| 2024-04-11 | Sale | BIENAIME JEAN JACQUES | director | 20,000 0.0105% | $90.99 | $1.82M | -22.35% |
| Davis George Eric | EVP, Chief Legal Officer | 61003 0.0315% | $3.4M | 4 | 75 | +5.04% |
| BIENAIME JEAN JACQUES | director | 474994 0.2454% | $26.44M | 26 | 321 | +29.88% |
| MEIER RICHARD A | 104032 0.0537% | $5.79M | 4 | 9 | +42.46% | |
| PRICE FREDRIC D | Chief Executive Officer | 79285 0.041% | $4.41M | 1 | 0 | <0.0001% |
| Mueller Brian | EVP, Chief Financial Officer | 72159 0.0373% | $4.02M | 2 | 32 | +36.78% |
| BAFFI ROBERT | EVP, Technical Operations | 71882 0.0371% | $4M | 8 | 30 | +11.93% |
| ASELAGE STEVE | EVP, Chief Business Officer | 59030 0.0305% | $3.29M | 7 | 25 | +10.2% |
| Cooper Jeffrey H | SVP, Chief Financial Officer | 41089 0.0212% | $2.29M | 4 | 26 | <0.0001% |
| KAKKIS EMIL D | Chief Medical Officer | 39621 0.0205% | $2.21M | 6 | 14 | +3.16% |
| KLEIN JOSEPH III | director | 35000 0.0181% | $1.95M | 3 | 4 | +42.82% |
| PYOTT DAVID E I | director | 30740 0.0159% | $1.71M | 1 | 0 | +0.47% |
| LAPALME PIERRE | director | 30150 0.0156% | $1.68M | 4 | 6 | +9.26% |
| Wood Mark | VP, Human Resources | 20277 0.0105% | $1.13M | 1 | 89 | +66.1% |
| Alles Mark J | director | 10905 0.0056% | $606,972.30 | 1 | 0 | +6.53% |
$159,914,414 | 243 | 18.52% | $8.86B | |
$273,531,368 | 93 | 38.24% | $9.16B | |
BioMarin Pharmaceutical Inc. (BMRN) | $2,765,836 | 72 | 20.00% | $10.77B |
$108,876,545 | 67 | 72.81% | $14.6B | |
$11,991,408 | 51 | 18.36% | $22.91B |
| Increased Positions | 282 | +37.65% | 34M | +18.74% |
| Decreased Positions | 345 | -46.06% | 26M | -14.31% |
| New Positions | 101 | New | 6M | New |
| Sold Out Positions | 132 | Sold Out | 6M | Sold Out |
| Total Postitions | 686 | -8.41% | 190M | +4.44% |
| Blackrock, Inc. | $1.31M | 11.48% | 22.05M | -2M | -8.15% | 2025-09-30 |
| Vanguard Group Inc | $1.1M | 9.68% | 18.58M | -421,247 | -2.22% | 2025-09-30 |
| Primecap Management Co/Ca/ | $905,381.00 | 7.93% | 15.23M | -542,886 | -3.44% | 2025-09-30 |
| Dodge & Cox | $873,130.00 | 7.65% | 14.69M | -421,509 | -2.79% | 2025-09-30 |
| State Street Corp | $521,055.00 | 4.57% | 8.76M | -83,152 | -0.94% | 2025-09-30 |
| Viking Global Investors Lp | $494,754.00 | 4.33% | 8.32M | -4M | -32.28% | 2025-09-30 |
| Aqr Capital Management Llc | $352,664.00 | 3.09% | 5.93M | +351,536 | +6.3% | 2025-09-30 |
| Geode Capital Management, Llc | $210,579.00 | 1.85% | 3.54M | +67,682 | +1.95% | 2025-09-30 |
| Millennium Management Llc | $156,188.00 | 1.37% | 2.63M | -207,145 | -7.31% | 2025-09-30 |
| Capital Research Global Investors | $150,860.00 | 1.32% | 2.54M | +2M | +547.55% | 2025-09-30 |